Search results
Results From The WOW.Com Content Network
Catabolite Activator Protein (blue) bound to a piece of DNA (red). In cell biology, catabolite activator protein (CAP), which is also known as cAMP receptor protein (CRP), is a trans-acting transcriptional activator in bacteria that effectively catalyzes the initiation of DNA transcription by interacting with RNA polymerase in a way that causes the DNA to bend.
In molecular biology, the five-prime cap (5′ cap) is a specially altered nucleotide on the 5′ end of some primary transcripts such as precursor messenger RNA. This process, known as mRNA capping , is highly regulated and vital in the creation of stable and mature messenger RNA able to undergo translation during protein synthesis .
Molecular & Cellular Proteomics is a monthly peer-reviewed scientific journal established in 2002 and published by the American Society for Biochemistry and Molecular Biology. [1] It covers research on structural and functional properties of proteins , especially with regard to development.
In 2013, Batut et al. [13] combined CAP trapper, template switching, and 5′-phosphate-dependent exonuclease digestion in RAMPAGE to maximize promoter specificity. In 2014, Murata et al. [ 14 ] published the nAnTi-CAGE protocol, where capped 5′ ends are sequenced on the Illumina platform with no PCR amplification and no tag cleavage.
The Kozak sequence was determined by sequencing of 699 vertebrate mRNAs and verified by site-directed mutagenesis. [7] While initially limited to a subset of vertebrates (i.e. human, cow, cat, dog, chicken, guinea pig, hamster, mouse, pig, rabbit, sheep, and Xenopus), subsequent studies confirmed its conservation in higher eukaryotes generally. [1]
No. of programs in 2023 [6] Notes Cytogentic Technologist: CT: 2: Diagnostic Molecular Scientist: DMS: 8: ... This page was last edited on 27 August 2024, ...
Navacaprant (developmental code names include BTRX-335140, BTRX-140, CYM-53093, NMRA-335140, and NMRA-140), is a selective κ-opioid receptor antagonist which is under development for the treatment of major depressive disorder.
This phenomenon, the process of which is called cap formation, was discovered in 1971 on lymphocytes [1] and is a property of amoebae and all locomotory animal cells except sperm. The crosslinking is most easily achieved using a polyvalent antibody to a surface antigen on the cell.